295 related articles for article (PubMed ID: 19633016)
1. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.
Wallentin L
Eur Heart J; 2009 Aug; 30(16):1964-77. PubMed ID: 19633016
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
Floyd CN; Passacquale G; Ferro A
Clin Pharmacokinet; 2012 Jul; 51(7):429-42. PubMed ID: 22568693
[TBL] [Abstract][Full Text] [Related]
3. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
Dovlatova NL; Jakubowski JA; Sugidachi A; Heptinstall S
J Thromb Haemost; 2008 Jul; 6(7):1153-9. PubMed ID: 18485086
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Niitsu Y; Jakubowski JA; Sugidachi A; Asai F
Semin Thromb Hemost; 2005 Apr; 31(2):184-94. PubMed ID: 15852222
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Mousa SA; Jeske WP; Fareed J
Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
[TBL] [Abstract][Full Text] [Related]
6. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.
Ancrenaz V; Daali Y; Fontana P; Besson M; Samer C; Dayer P; Desmeules J
Curr Drug Metab; 2010 Oct; 11(8):667-77. PubMed ID: 20942779
[TBL] [Abstract][Full Text] [Related]
7. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Savi P; Herbert JM
Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
[TBL] [Abstract][Full Text] [Related]
8. Prasugrel: a novel antiplatelet agent.
Riley AB; Tafreshi MJ; Haber SL
Am J Health Syst Pharm; 2008 Jun; 65(11):1019-28. PubMed ID: 18499874
[TBL] [Abstract][Full Text] [Related]
9. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Wijeyeratne YD; Joshi R; Heptinstall S
Expert Rev Clin Pharmacol; 2012 May; 5(3):257-69. PubMed ID: 22697589
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
Farid NA; Kurihara A; Wrighton SA
J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
[TBL] [Abstract][Full Text] [Related]
12. Prasugrel.
Tantry US; Bliden KP; Gurbel PA
Expert Opin Investig Drugs; 2006 Dec; 15(12):1627-33. PubMed ID: 17107286
[TBL] [Abstract][Full Text] [Related]
13. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
Tcheng JE; Mackay SM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):83-91. PubMed ID: 22316323
[TBL] [Abstract][Full Text] [Related]
14. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
15. ADP receptor antagonism: what's in the pipeline?
Angiolillo DJ
Am J Cardiovasc Drugs; 2007; 7(6):423-32. PubMed ID: 18076209
[TBL] [Abstract][Full Text] [Related]
16. [Myocardial infarction: Role of new antiplatelet agents].
Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
[TBL] [Abstract][Full Text] [Related]
17. [Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel].
Abbate R; Crea F; De Servi S; Filippi E; Gensini GF; Golinos P; Savonitto S
G Ital Cardiol (Rome); 2010 Feb; 11(2):127-37. PubMed ID: 20408476
[TBL] [Abstract][Full Text] [Related]
18. [Prasugrel, a new thienopyridine].
Schrör K; Huber K
Hamostaseologie; 2007 Dec; 27(5):351-5. PubMed ID: 18060245
[TBL] [Abstract][Full Text] [Related]
19. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
[TBL] [Abstract][Full Text] [Related]
20. Metabolic differences of current thienopyridine antiplatelet agents.
Fareed J; Jeske W; Thethi I
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):307-17. PubMed ID: 23289968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]